TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods
- PMID: 38626948
- PMCID: PMC11019967
- DOI: 10.1136/bmj-2023-078378
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods
Erratum in
-
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods.BMJ. 2024 Apr 18;385:q902. doi: 10.1136/bmj.q902. BMJ. 2024. PMID: 38636956 Free PMC article. No abstract available.
Abstract
The TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) statement was published in 2015 to provide the minimum reporting recommendations for studies developing or evaluating the performance of a prediction model. Methodological advances in the field of prediction have since included the widespread use of artificial intelligence (AI) powered by machine learning methods to develop prediction models. An update to the TRIPOD statement is thus needed. TRIPOD+AI provides harmonised guidance for reporting prediction model studies, irrespective of whether regression modelling or machine learning methods have been used. The new checklist supersedes the TRIPOD 2015 checklist, which should no longer be used. This article describes the development of TRIPOD+AI and presents the expanded 27 item checklist with more detailed explanation of each reporting recommendation, and the TRIPOD+AI for Abstracts checklist. TRIPOD+AI aims to promote the complete, accurate, and transparent reporting of studies that develop a prediction model or evaluate its performance. Complete reporting will facilitate study appraisal, model evaluation, and model implementation.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: support from the funding bodies listed above for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. GSC is a National Institute for Health and Care Research (NIHR) senior investigator, the director of the UK EQUATOR Centre, editor-in-chief of BMC Diagnostic and Prognostic Research, and a statistics editor for The BMJ. KGMM is director of Health Innovation Netherlands and editor-in-chief of BMC Diagnostic and Prognostic Research. RDR is an NIHR senior investigator, a statistics editor for The BMJ, and receives royalties from textbooks Prognosis Research in Healthcare and Individual Participant Data Meta-Analysis. AKD is an NIHR senior investigator. EWL is the head of research at The BMJ. BG is a part time employee of HeartFlow and Kheiron Medical Technologies and holds stock options with both as part of the standard compensation package. SR receives royalties from Springer for the textbooks Targeted Learning: Causal Inference for Observational and Experimental Data and Targeted Learning: Causal Inference for Complex Longitudinal Studies. JCC receives honorariums as a current lay member on the UK NICE covid-19 expert panel and a citizen partner on the COVID-END Covid-19 Evidence Network to support decision making; was a lay member on the UK NIHR AI AWARD panel in 2020-22 and is a current lay member on the UK NHS England AAC Accelerated Access Collaborative NHS AI Laboratory Evaluation Advisory Group; is a patient fellow of the European Patients’ Academy on Therapeutic Innovation and a EURORDIS rare disease alumni; reports grants from the UK National Institute for Health and Care Research, European Commission, UK Cell Gene Catapult, University College London, and University of East Anglia; reports patient speaker fees from MEDABLE, Reuters Pharma events, Patients as Partners Europe, and EIT Health Scandinavia; reports consultancy fees from Roche Global, GlaxoSmithKline, the FutureScience Group and Springer Healthcare (scientific publishing), outside of the scope of the present work; and is a strategic board member of the UK Medical Research Council IASB Advanced Pain Discovery Platform initiative, Plymouth Institute of Health, and EU project Digipredict Edge AI-deployed Digital Twins for covid-19 Cardiovascular Disease. ALB is a paid consultant for Generate Biomedicines, Flagship Pioneering, Porter Health, FL97, Tessera, FL85; has an equity stake in Generate Biomedicines; and receives research funding support from GlaxoSmithKline, National Heart, Lung, and Blood Institute, and National Institute of Diabetes and Digestive and Kidney Diseases. No other conflicts of interests with this specific work are declared.
Comment in
-
TRIPOD+AI: an updated reporting guideline for clinical prediction models.BMJ. 2024 Apr 16;385:q824. doi: 10.1136/bmj.q824. BMJ. 2024. PMID: 38626949 No abstract available.
Similar articles
-
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement.Eur J Clin Invest. 2015 Feb;45(2):204-14. doi: 10.1111/eci.12376. Epub 2015 Jan 5. Eur J Clin Invest. 2015. PMID: 25623047
-
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement.Ann Intern Med. 2015 Jan 6;162(1):55-63. doi: 10.7326/M14-0697. Ann Intern Med. 2015. PMID: 25560714
-
Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement.Eur Urol. 2015 Jun;67(6):1142-1151. doi: 10.1016/j.eururo.2014.11.025. Epub 2015 Jan 5. Eur Urol. 2015. PMID: 25572824
-
TRIPOD+AI: an updated reporting guideline for clinical prediction models.BMJ. 2024 Apr 16;385:q824. doi: 10.1136/bmj.q824. BMJ. 2024. PMID: 38626949 No abstract available.
-
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.BMJ. 2015 Jan 7;350:g7594. doi: 10.1136/bmj.g7594. BMJ. 2015. PMID: 25569120 Review.
Cited by
-
Deep Convolutional Neural Network for Accurate Classification of Myofibroblastic Lesions on Patch-Based Images.Head Neck Pathol. 2024 Oct 28;18(1):117. doi: 10.1007/s12105-024-01723-5. Head Neck Pathol. 2024. PMID: 39466448
-
Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy.BMC Neurol. 2024 Oct 25;24(1):415. doi: 10.1186/s12883-024-03903-w. BMC Neurol. 2024. PMID: 39455929 Free PMC article.
-
Machine learning algorithms: why the cup occasionally appears half-empty.Eur J Clin Nutr. 2024 Oct 23. doi: 10.1038/s41430-024-01529-2. Online ahead of print. Eur J Clin Nutr. 2024. PMID: 39443687 No abstract available.
-
Development and validation of a nomogram to predict the risk of adjacent segment disease after transforaminal lumbar interbody fusion in patients with lumbar degenerative diseases.J Orthop Surg Res. 2024 Oct 22;19(1):680. doi: 10.1186/s13018-024-05170-4. J Orthop Surg Res. 2024. PMID: 39438978 Free PMC article.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources